Cytomegalovirus infection and prophylaxis in renal transplantation: financial considerations

Transplant Proc. 1998 Jun;30(4):1318-9. doi: 10.1016/s0041-1345(98)00258-9.
No abstract available

MeSH terms

  • Acyclovir / economics
  • Acyclovir / therapeutic use
  • Antiviral Agents / economics
  • Antiviral Agents / therapeutic use
  • Cadaver
  • Costs and Cost Analysis
  • Cytomegalovirus Infections / economics
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus Infections / prevention & control
  • Graft Survival*
  • Hospitals, Community
  • Humans
  • Kidney Transplantation / economics*
  • Kidney Transplantation / mortality
  • Kidney Transplantation / physiology*
  • Living Donors
  • Postoperative Complications / economics
  • Postoperative Complications / epidemiology
  • Survival Rate
  • Texas
  • Tissue Donors

Substances

  • Antiviral Agents
  • Acyclovir